Dr. Doyle is a proven research physician who has held numerous leadership roles in clinical development. She currently serves as Chief Medical Officer of Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines. Prior to joining Aro, Dr. Doyle served as Vice President, Global Therapeutic Area Head, Immunology at CSL Behring. Prior to her time at CSL, Dr. Doyle held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals. During her career, she has led clinical development across a broad range of immune mediated and orphan diseases and led teams with responsibilities for design and execution of first-in-human through Phase 2 and3 trials, resulting in several global regulatory approvals. Dr. Doyle received an M.D. from Yale Medical School and completed her postdoctoral training at Harvard Medical School, including a residency in internal medicine at Massachusetts General Hospital and clinical/research fellowship in rheumatology and immunology at Brigham and Women’s Hospital. She received a B.A. from Princeton University.